Intrahepatic cholangiocarcinoma: Management options and emerging therapies

Journal of the American College of Surgeons

Volumn 217, Issue 4, 2013, Pages

  Dodson, Rebecca M ^a   Weiss, Matthew J ^a   Cosgrove, David ^a   Herman, Joseph M ^a   Kamel, Ihab ^a   Anders, Robert ^a   Geschwind, Jean Francois H ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LAPATINIB; LOMUSTINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB;

ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURGERY; CAROLI DISEASE; CHEMOEMBOLIZATION; COLONOSCOPY; COMMON BILE DUCT CYST; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARASITOSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84884531679     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2013.05.021     Document Type: Review

References (148)

1. M. Aljiffry, A. Abdulelah, and M. Walsh Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature J Am Coll Surg 208 2009 134 147
2. H. Nathan, T.M. Pawlik, and C.L. Wolfgang Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis J Gastroint Surg 11 200& 1488 1496 discussion 1496-1497
3. J.C. Tan, N.G. Coburn, and N.N. Baxter Surgical management of intrahepatic cholangiocarcinoma-a population-based study Ann Surg Oncol 15 2008 600 608
4. H. Nathan, T.A. Aloia, and J.N. Vauthey A proposed staging system for intrahepatic cholangiocarcinoma Ann Surg Oncol 16 2009 14 22
5. Y.H. Shaib, J.A. Davila, K. McGlynn, and H.B. El-Serag Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40 2004 472 477
6. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 1& 2010 1471 1474
7. T. Patel Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States Hepatology 33 2001 1353 1357
8. S.A. Khan, H.C. Thomas, B.R. Davidson, and S.D. Taylor-Robinson Cholangiocarcinoma Lancet 366 2005 1303 1314
9. S.A. Khan, M.B. Toledano, and S.D. Taylor-Robinson Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma HPB 10 2008 7& 82
10. C.W. Hammill, and L.L. Wong Intrahepatic cholangiocarcinoma: a malignancy of increasing importance J Am Coll Surg 20& 2008 594 603
11. S.D. Taylor-Robinson, G.R. Foster, and S. Arora Increase in primary liver cancer in the UK, 1979-94 Lancet 350 199& 1142 1143
12. I. Kato, T. Kuroishi, and S. Tominaga Descriptive epidemiology of subsites of cancers of the liver, biliary tract and pancreas in Japan Japan J Clin Oncol 20 1990 232 237
13. U. Broome, R. Olsson, and L. Loof Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis Gut 38 1996 610 615
14. N. Chalasani, A. Baluyut, and A. Ismail Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study Hepatology 31 2000 & 11
15. M.F. Chen Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment J Gastroenterol Hepatol 14 1999 1144 1149
16. K. Okuda, Y. Nakanuma, and M. Miyazaki Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology J Gastroenterol Hepatol 1& 2002 1049 1055
17. T.M. Welzel, B.I. Graubard, and H.B. El-Serag Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study Clin Gastroenterol Hepatol 5 200& 1221-1128
18. V. Perumal, J. Wang, and P. Thuluvath Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States Human Pathol 3& 2006 1211 1216
19. H.R. Shin, C.U. Lee, and H.J. Park Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea Int J Epidemiol 25 1996 933 940
20. H. Zhou, H. Wang, and D. Zhou Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis Eur J Cancer 46 2010 1056 1061
21. F. Donato, U. Gelatti, and A. Tagger Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy Cancer Causes Control 12 2001 959 964
22. Y.H. Shaib, H.B. El-Serag, and J.A. Davila Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study Gastroenterol 128 2005 620 626
23. O. Farges, and D. Fukes Chirurgie des cholangiocarcinomes intrahépatiques hilaires et vésiculaires: rapport présenté au 111e Congrès français de chirurgie, Paris, 30 septembre-2 octobre 2009 2009 Arnette Rueil-Malmaison
24. H. Lang, G.C. Sotiropoulos, and N.R. Fruhauf Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 2& resections in 50 patients over a 5-year period Ann Surg 241 2005 134 143
25. K.Y. Paik, J.C. Jung, and J.S. Heo What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 23 2008 766 770
26. G. Morris-Stiff, M. Teli, N. Jardine, and M.C. Puntis CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease Hepatobiliary Pancreatic Dis Intl 8 2009 620 626
27. J.C. Nichols, G.J. Gores, and N.F. LaRusso Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis Mayo Clin Proc 68 1993 874 879
28. D. Tamandl, B. Herberger, and B. Gruenberger Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma Ann Surg Oncol 15 2008 278& 2794
29. I. Ikai, S. Arii, and M. Okazaki Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan Hepatol Res 3& 200& 676 691
30. G.A. Poultsides, A.X. Zhu, M.A. Choti, and T.M. Pawlik Intrahepatic cholangiocarcinoma Surg Clin North Am 90 2010 81& 837
31. Y. Nakanuma, Y. Sato, and K. Harada Pathological classification of intrahepatic cholangiocarcinoma based on a new concept World J Hepatol 2 2010 419 427
32. Y. Maetani, K. Itoh, and C. Watanabe MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation Am J Roentgenol 176 2001 1499 1507
33. G.M. Nesbit, C.D. Johnson, and E.M. James Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography Am J Roentgenol 151 1988 933 938
34. T.K. Kim, B.I. Choi, and J.K. Han Peripheral cholangiocarcinoma of the liver: two-phase spiral CT findings Radiology 204 199& 539 543
35. J.M. Lacomis, R.L. Baron, and J.H. Oliver 3rd Cholangiocarcinoma: delayed CT contrast enhancement patterns Radiology 203 199& 98 104
36. K. Takayasu, S. Ikeya, and K. Mukai CT of hilar cholangiocarcinoma: late contrast enhancement in six patients Am J Roentgenol 154 1990 1203 1206
37. H. Honda, H. Onitsuka, and K. Yasumori Intrahepatic peripheral cholangiocarcinoma: two-phased dynamic incremental CT and pathologic correlation J Comput Assist Tomogr 1& 1993 39& 402
38. C.D. Anderson, M.H. Rice, and C.W. Pinson Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma J Gastrointest Surg 8 2004 90 97
39. Y.J. Kim, M. Yun, and W.J. Lee Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma Eur J Nucl Med Mol Imaging 30 2003 146& 1472
40. H. Petrowsky, P. Wildbrett, and D.B. Husarik Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma J Hepatol 45 2006 43 50
41. D. Goere, G.D. Wagholikar, and P. Pessaux Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma Surg Endosc 20 2006 721 725
42. S.M. Weber, W.R. Jarnagin, and D. Klimstra Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes J Am Coll Surg 193 2001 384 391
43. P. Ghali, P.J. Marotta, and E.M. Yoshida Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience Liver Transplant 11 2005 1412 1416
44. D.J. Rea, J.K. Heimbach, and C.B. Rosen Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma Ann Surg 242 2005 451 458 discussion 458-461
45. T. Nakagohri, T. Asano, and H. Kinoshita Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma World J Surg 2& 2003 289 293
46. K. Inoue, M. Makuuchi, and T. Takayama Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma Surgery 12& 2000 498 505
47. T. Uenishi, S. Kubo, and O. Yamazaki Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases J Hepato-Biliary-Pancreatic Surg 15 2008 41& 422
48. M.L. DeOliveira, S.C. Cunningham, and J.L. Cameron Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution Ann Surg 245 200& 755 762
49. Y.Y. Jan, C.N. Yeh, and T.S. Yeh Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma World J Surg 29 2005 894 898
50. I. Endo, M. Gonen, and A.C. Yopp Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection Ann Surg 248 2008 84 96
51. T. Nakagohri, T. Kinoshita, and M. Konishi Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma World J Surg 32 2008 2675 2680
52. K. Shimada, T. Sano, and S. Nara Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement Surgery 145 2009 411 416
53. S.B. Choi, K.S. Kim, and J.Y. Choi The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival Ann Surg Oncol 16 2009 3048 3056
54. M. Ohtsuka, H. Ito, and F. Kimura Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival Br J Surg 89 2002 1525 1531
55. A. Weimann, H. Varnholt, and H.J. Schlitt Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma Br J Surg 8& 2000 1182 1187
56. A. Guglielmi, A. Ruzzenente, and T. Campagnaro Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection World J Surg 33 2009 124& 1254
57. D. Ribero, A.D. Pinna, and A. Guglielmi Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients Arch Surg 20 2012 1 7
58. M. Yamamoto, K. Takasaki, and T. Otsubo Recurrence after surgical resection of intrahepatic cholangiocarcinoma J Hepato-Biliary-Pancreatic Surg 8 2001 154 157
59. O. Hyder, I. Hatzaras, and G.C. Sotiropoulos Recurrence after operative management of intrahepatic cholangiocarcinoma Surgery 153 2013 811 818
60. A. Valverde, N. Bonhomme, and O. Farges Resection of intrahepatic cholangiocarcinoma: a Western experience J Hepato-Biliary-Pancreatic Surg 6 1999 122 127
61. M.M. Konstadoulakis, S. Roayaie, and I.P. Gomatos Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome Surgery 143 2008 366 374
62. C.G. Meyer, I. Penn, and L. James Liver transplantation for cholangiocarcinoma: results in 20& patients Transplantation 69 2000 1633 1637
63. M. Shimoda, D.G. Farmer, and S.D. Colquhoun Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature Liver Transplant & 2001 1023 1033
64. R. Robles, J. Figueras, and V.S. Turrion Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma Ann Surg 239 2004 265 271
65. B. Brandsaeter, H. Isoniemi, and U. Broome Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy J hepatol 40 2004 815 822
66. J.A. Goss, C.R. Shackleton, and D.G. Farmer Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience Ann Surg 225 199& 472 481 discussion 481-483
67. M. Shimada, Y. Yamashita, and S. Aishima Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma Br J Surg 88 2001 1463 1466
68. M.C. de Jong, H. Nathan, and G.C. Sotiropoulos Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment J Clin Oncol 29 2011 3140 3145
69. T. Nakagawa, T. Kamiyama, and N. Kurauchi Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma World J Surg 29 2005 728 733
70. S. Suzuki, T. Sakaguchi, and Y. Yokoi Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma World J Surg 26 2002 68& 693
71. D. Tamandl, K. Kaczirek, and B. Gruenberger Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma Br J Surg 96 2009 919 925
72. O. Farges, D. Fuks, and Y.P. Le Treut AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group Cancer 11& 2011 2170 2177
73. T. Okabayashi, J. Yamamoto, and T. Kosuge A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables Cancer 92 2001 2374 2383
74. S. Jonas, A. Thelen, and C. Benckert Extended liver resection for intrahepatic cholangiocarcinoma: A comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification Ann Surg 249 2009 303 309
75. K. Shimada, T. Sano, and Y. Sakamoto Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma World J Surg 31 200& 2016 2022
76. S. Yamasaki Intrahepatic cholangiocarcinoma: macroscopic type and stage classification J Hepato-Biliary-Pancreatic Surg 10 2003 288 291
77. G.W. Song, S.G. Lee, and Y.J. Lee Analysis of survival and factors affecting the survival after surgical resection of peripheral cholangiocarcinoma: 318 cases in single institute Korean J Hepatol 13 200& 208 221
78. G. Ercolani, G.L. Grazi, and M. Ravaioli The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy Ann Surg 239 2004 202 209
79. T. Ignami, T. Ebata, and Y. Yokoyama Staging of peripheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications World J Surg 35 2011 2501 2509
80. F.F. Chou, S.M. Sheen-Chen, and Y.S. Chen Surgical treatment of cholangiocarcinoma Hepato-Gastroenterol 44 199& 760 765
81. T. Todoroki Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery Hepato-Gastroenterol 4& 2000 644 649
82. M. Ducreux, P. Rougier, and A. Fandi Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin Ann Oncol 9 1998 653 656
83. M.A. Lee, I.S. Woo, and J.H. Kang Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma J Cancer Res Clin Oncol 130 2004 346 350
84. M. Raderer, M.H. Hejna, and J.B. Valencak Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer Oncology 56 1999 17& 180
85. S. Kubicka, K.L. Rudolph, and M.K. Tietze Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas Hepato-Gastroenterol 48 2001 783 789
86. T. Kiba, T. Nishimura, and S. Matsumoto Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature Oncology 70 2006 358 365
87. W. Scheithauer Review of gemcitabine in biliary tract carcinoma Sem Oncol 29 2002 40 45
88. G.W. Lee, J.H. Kang, and H.G. Kim Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma Am J Clin Oncol 29 2006 12& 131
89. J.J. Knox, D. Hedley, and A. Oza Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2005 2332 2338
90. T. Andre, C. Tournigand, and O. Rosmorduc Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 2004 1339 1343
91. F. Eckel, and R.M. Schmid Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 200& 896 902
92. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
93. T. Okusaka, K. Nakachi, and A. Fukutomi Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Br J Cancer 103 2010 469 474
94. Y. Murakami, K. Uemura, and T. Sudo Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors J Hepato-Biliary-Pancreatic Sci 19 2012 306 313
95. S.B. Fisher, S.H. Patel, and D.A. Kooby Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis HPB 14 2012 514 522
96. T. Isa, S. Tomita, and A. Nakachi Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma Hepato-Gastroenterol 49 2002 604 608
97. C. Bengala, F. Bertolini, and N. Malavasi Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial Br J Cancer 102 2010 68 72
98. A.X. Zhu, J.A. Meyerhardt, and L.S. Blaszkowsky Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study Lancet Oncol 11 2010 48 54
99. B. Gruenberger, J. Schueller, and U. Heubrandtner Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncol 11 2010 1142 1148
100. J. Lee, S.H. Park, and H.M. Chang Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Lancet Oncol 13 2012 181 188
101. R.K. Ramanathan, C.P. Belani, and D.A. Singh A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Cancer Chemother Pharmacol 64 2009 77& 783
102. Z.C. Zeng, Z.Y. Tang, and J. Fan Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients Cancer J 12 2006 113 122
103. Y.X. Chen, Z.C. Zeng, and Z.Y. Tang Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients BMC Cancer 10 2010 492
104. E.T. Shinohara, N. Mitra, M. Guo, and J.M. Metz Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma International J Radiat Oncol Biol Phys 72 2008 1495 1501
105. J.H. Kim, H.J. Won, and Y.M. Shin Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma Am J Roentgenol 196 2011 W205 W209
106. Y. Fu, W. Yang, and W. Wu Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma J Vasc Intervent Radiol 23 2012 642 649
107. N.J. Gusani, F.K. Balaa, and J.L. Steel Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience J Gastrointest Surg 12 2008 129 137
108. W.R. Jarnagin, L.H. Schwartz, and D.H. Gultekin Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival Ann Oncol 20 2009 1589 1595
109. K. Shitara, I. Ikami, and M. Munakata Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma Clin Oncol (R Coll Radiol) 20 2008 241 246
110. M. Cantore, A. Mambrini, and G. Fiorentini Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors Cancer 103 2005 1402 1407
111. N. Tanaka, K. Yamakado, and A. Nakatsuka Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience Eur J Radiol 41 2002 42 48
112. J.H. Kim, H.K. Yoon, and K.B. Sung Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes Cancer 113 2008 1614 1622
113. C. Aliberti, G. Benea, M. Tilli, and G. Fiorentini Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results Cardiovasc Intervent Radiol 31 2008 883 888
114. R.T. Hoffmann, P.M. Paprottka, and A. Schon Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival Cardiovasc Intervent Radiol 35 2012 105 116
115. L.E. Harrison, Y. Fong, and D.S. Klimstra Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma Br J Surg 85 1998 1068 1070
116. H. Lang, G.C. Sotiropoulos, and G. Sgourakis Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients J Am Coll Surg 208 2009 218 228
117. W.F. Shen, W. Zhong, and F. Xu Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma World J Gastroenterol 15 2009 5976 5982
118. S.Y. Cho, S.J. Park, and S.H. Kim Survival analysis of intrahepatic cholangiocarcinoma after resection Ann Surg Oncol 1& 2010 1823 1830
119. G. Ercolani, G. Vetrone, and G.L. Grazi Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival Ann Surg 252 2010 10& 114
120. A. Saxena, T.C. Chua, and A. Sarkar Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit J Gastrointest Surg 14 2010 1128 1138
121. M.C. Ellis, M.A. Cassera, and J.T. Vetto Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors HPB 13 2011 59 63
122. S.M. Ali, C.J. Clark, and V.M. Zaydfudim Role of major vascular resection in patients with intrahepatic cholangiocarcinoma Ann Surg Oncol 20 2013 2023 2028
123. P.A. Ellis, A. Norman, and A. Hill Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours Eur J Cancer 31A 1995 1594 1598
124. C.W. Choi, I.K. Choi, and J.H. Seo Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas Am J Clin Oncol 23 2000 425 428
125. J. Taieb, E. Mitry, and V. Boige Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma Ann Oncol 13 2002 1192 1196
126. Y.Z. Patt, M.M. Hassan, and R.D. Lozano Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer Clin Cancer Res & 2001 3375 3380
127. O. Nehls, B. Klump, and H.T. Arkenau Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial Br J Cancer 8& 2002 702 704
128. S. Rao, D. Cunningham, and R.E. Hawkins Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer Br J Cancer 92 2005 1650 1654
129. P. Papakostas, C. Kouroussis, and N. Androulakis First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study Eur J Cancer 3& 2001 1833 1838
130. Y.Z. Patt, M.M. Hassan, and A. Aguayo Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma Cancer 101 2004 578 586
131. O. Nehls, H. Oettle, and J.T. Hartmann Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial Br J Cancer 98 2008 309 315
132. V. Gebbia, F. Giuliani, and E. Maiello Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study J Clin Oncol 19 2001 4089 4091
133. R. Kuhn, A. Hribaschek, and K. Eichelmann Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas Invest New Drugs 20 2002 351 356
134. C. Hsu, Y.C. Shen, and C.H. Yang Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract Br J Cancer 90 2004 1715 1719
135. G.V. Kornek, B. Schuell, and F. Laengle Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial Ann Oncol 15 2004 478 483
136. J.Y. Cho, Y.H. Paik, and Y.S. Chang Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma Cancer 104 2005 2753 2758
137. J.S. Park, S.Y. Oh, and S.H. Kim Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study Japan J Clin Oncol 35 2005 68 73
138. S. Thongprasert, S. Napapan, C. Charoentum, and S. Moonprakan Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 16 2005 279 281
139. R.P. Riechelmann, C.A. Townsley, and S.N. Chin Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer Cancer 110 200& 130& 1312
140. D. Koeberle, P. Saletti, and M. Borner Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research J Clin Oncol 26 2008 3702 3708
141. T. Sasaki, H. Isayama, and Y. Nakai Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer Cancer Chemother Pharmacol 65 2010 1101 1107
142. H. Safran, T. Miner, and M. Resnick Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer Am J Clin Oncol 31 2008 140 144
143. J. Peck, L. Wei, and M. Zalupski HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib Oncology 82 2012 175 179
144. B. Paule, M.O. Herelle, and E. Rage Cetuximab plus gemcitabine- oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas Oncology 72 200& 105 110
145. J.H. Yi, S. Thongprasert, and J. Lee A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study Eur J Cancer 48 2012 196 201
146. P.A. Philip, M.R. Mahoney, and C. Allmer Phase II study of erlotinib in patients with advanced biliary cancer J Clin Oncol 24 2006 3069 3074
147. S.J. Lubner, M.R. Mahoney, and J.L. Kolesar Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study J Clin Oncol 28 2010 3491 3497
148. L.H. Jensen, J. Lindebjerg, and J. Ploen Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer Ann Oncol 23 2012 2341 2346